Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) COGS-to-Revenue : 0.00 (As of Mar. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Regenerx Biopharmaceuticals COGS-to-Revenue?

Regenerx Biopharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2023 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2023 was $0.02 Mil.

Regenerx Biopharmaceuticals's COGS to Revenue for the three months ended in Mar. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Regenerx Biopharmaceuticals's Gross Margin % for the three months ended in Mar. 2023 was N/A%.

Regenerx Biopharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Regenerx Biopharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerx Biopharmaceuticals COGS-to-Revenue Chart

Regenerx Biopharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

Regenerx Biopharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Regenerx Biopharmaceuticals COGS-to-Revenue Calculation

Regenerx Biopharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.077
	=	0.00

Regenerx Biopharmaceuticals's COGS to Revenue for the quarter that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.019
	=	0.00

Regenerx Biopharmaceuticals (OTCPK:RGRX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Regenerx Biopharmaceuticals's Gross Margin % for the three months ended in Mar. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0.019
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Regenerx Biopharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerx Biopharmaceuticals Inc (OTCPK:RGRX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850

Website

https://www.regenerx.com

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.

Executives

Aptafin S P A	other: Member of 10% owner group	VIALE SHAKESPEARE 47, ROME L6 00144
Alessandro Noseda	director	C/O 15245 SHADY GROVE ROAD, SUITE 470, ROCKVILLE MD 20850
S.a. Sinaf	10 percent owner	26 BOULEVARD ROYAL, LUXEMBOURG N4 L-2449
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Francesca Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Preta Martina Cavazza	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Mauro Bove	director	C/O REGENERX BIOPHARMACEUTICALS, INC., 3 BETHESDA METRO CENTER - SUITE 630, BETHESDA MD 20814
R Don Elsey	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
J J Finkelstein	director
Joseph C Mcnay	director	3 BETHESDA METRO CENTER STE 700, C/O REGENERX BIOPHARMACEUTICALS INC, BETHESDA MD 20814
Allan L Goldstein	director
Dane R Saglio	officer: Chief Financial Officer
Aria Digital	10 percent owner	22ND FL, PARKVIEW TOWER,, 248 JUNGJAIL-RO, BUNDANG-GU,, SEONGNAM-SI, GYEONGGI-DO M4 463-863